Avantor (AVTR) Q3 2025 earnings summary

Executive summary

• Q3 2025 net sales were $1.62 billion, down 5.3% year-over-year, with a 4.7% organic decline, driven by the Clinical Services divestiture and reduced demand in Laboratory Solutions.

• Net loss was $711.8 million, primarily due to a $785 million non-cash goodwill impairment charge in the Distribution reporting unit.

• Adjusted EBITDA was $267.9 million (16.5% margin), with adjusted EPS at $0.22.

• Free cash flow reached $172 million, with 124% conversion.

• Leadership changes include Gregory T. Lucier joining the Board, Gregory L. Summe to become Chairman in 2026, and a new CEO launching the "Avantor Revival" turnaround strategy focused on simplification, operational improvement, and accountability.

Financial highlights

• Q3 2025 revenue was $1.62 billion, down 5% year-over-year on an organic basis, with adjusted gross profit at $527 million (32.4% margin), down 100 basis points year-over-year.

• Adjusted EBITDA margin was 16.5%, and adjusted operating income margin was 14.6%.

• Free cash flow for Q3 was $172 million, with operating cash flow at $207.4 million.

• Adjusted net income was $151.1 million, compared to $175.2 million in Q3 2024.

• A $785 million non-cash goodwill impairment was taken for the Lab distribution business due to share price weakness and margin headwinds.

Outlook and guidance

• Full-year 2025 organic revenue growth is expected at negative 3.5% to negative 2.5%, with reported revenue growth of negative 4% to negative 3%.

• Adjusted EBITDA margin is projected in the mid-16% range; adjusted EPS guidance is $0.88 to $0.92.

• Free cash flow is expected between $550 million and $600 million before one-time expenses.

• Cost transformation initiative is expected to generate $400 million in run rate gross savings by the end of 2027.

• Inflationary pressures and foreign currency fluctuations are expected to continue impacting results.